Clinical Trial

Does Vessel-sparing Surgery in Anterior Approach Total Hip Arthroplasty Change Clinical Outcome?

Study acronym: USP
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 15, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
During direct anterior approach (DAA) for total hip arthroplasty (THA), ligation of the lateral femoral circumflex artery and vessel is always conducted. However, this standardized procedure may jeopardize blood muscle perfusion and cause tenderness in the tensor fascia lata muscle. The investigators want to investigate whether blood vessel-sparing surgery is feasible, reproducible, and would alter outcomes following DAA THA. The surgical technique of the vessel-sparing procedure will be described and investigated in a prospective blinded RCT. The investigators hypothesize that the vessel-sparing technique is feasible in 60% of the patients. If these vessels were not sacrificed, the investigators expect the incidence of TFL tendinopathy to be lower.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-05.
Status change: Not Yet Recruiting → Recruiting 2024-11-12
Trial Details
NCT Number NCT06308965
Lead Sponsor Ziekenhuis Oost-Limburg
Conditions Tensor Fasciae Latae Syndrome, Arthroplasty Complications
Enrollment 300 participants
Start Date 2024-06-11
Primary Completion 2025-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2024-11-15